Lunasin, a novel seed peptide, sensitizes human breast cancer MDA-MB-231 cells to aspirin-arrested cell cycle and induced apoptosis

Chemico-Biological Interactions

Volumn 186, Issue 2, 2010, Pages 127-134

  Hsieh, Chia Chien ^a   Hernández Ledesma, Blanca ^a,b   de Lumen, Ben O ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b INSTITUTO DE FERMENTACIONES INDUSTRIALES CSIC   (Spain)

Author keywords

Apoptosis; Aspirin; Breast cancer cell; Cell cycle arrest; Lunasin

Indexed keywords

ACETYLSALICYLIC ACID; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LUNASIN; PHOSPHOTRANSFERASE; PROTEIN C JUN; PROTEIN FOS; PROTEIN KINASE B; PROTEIN PIK3R1; UNCLASSIFIED DRUG; VEGETABLE PROTEIN;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; DRUG SENSITIZATION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

AMINO ACID SEQUENCE; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; ASPIRIN; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENE EXPRESSION; HUMANS; MOLECULAR SEQUENCE DATA; SIGNAL TRANSDUCTION; SOYBEAN PROTEINS;

EID: 77953541212     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2010.04.027     Document Type: Article

References (37)

1. Sledge G.W. Breast cancer as a world challenge. Clin. Breast Cancer 2004, 5:11.
2. Liu R.H. Potential synergy of phytochemicals in cancer prevention: mechanism of action. J. Nutr. 2004, 134:3479S-3485S.
3. Constantinou A.I., White B.E.P., Tonetti D., Yang Y., Liang W., Li W., van Breemen R.B. The soy isoflavone daidzein improves the capacity of tamoxifen to prevent mammary tumours. Eur. J. Cancer 2005, 41:647-654.
4. Li Y., Ahmed F., Ali S., Philip P.A., Kucuk O., Sarkar F.H. Inactivation of nuclear factor B by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. Cancer Res. 2005, 65:6934-6942.
5. Sporn M.B., Suh N. Chemoprevention of cancer. Carcinogenesis 2000, 21:525-530.
6. Johnson T.W., Anderson K.E., Lazovich D., Folsom A.R. Association of aspirin and nonsteroidal anti-inflammatory drug use with breast cancer. Cancer Epidemiol. Biomarkers 2002, 11:1586-1591.
7. Abbadessa G., Spaccamiglio A., Sartori M.L., Nebbia C., Dacasto M., Di Carlo F., Racca S. The aspirin metabolite, salicylate, inhibits 7,12-dimethylbenz[a]anthracene-DNA adduct formation in breast cancer cells. Int. J. Oncol. 2006, 28:1131-1140.
8. Lu M.L., Strohecker A., Chen F., Kwan T., Bosman J., Jordan V.C., Cryns V.L. Aspirin sensitizes cancer cells to TRAIL-induced apoptosis by reducing survivin levels. Clin. Cancer Res. 2008, 14:3168-3176.
9. Uluçkan Ö., Eagleton M.C., Floyd D.H., Morgan E.A., Hirbe A.C., Kramer M., Dowland N., Prior J.L., Piwnica-Worms D., Jeong S.S., Chen R., Weilbaecher K. APT102, a novel ADPase, cooperates with aspirin to disrupt bone metastasis in mice. J. Cell Biochem. 2008, 104:1311-1323.
10. Singh-Ranger G., Salhab M., Mokbel K. The role of cyclooxygenase-2 in breast cancer: review. Breast Cancer Res. Treat. 2008, 109:189-198.
11. Adlercreutz C.H., Goldin B.R., Gorbach S.L., Hockerstedt K.A.V., Watanabe S., Hamalainen E.K., Markkanen M.H., Makela T.H., Hase T.A., Fotsis T. Soybean phytoestrogen intake and cancer risk. J. Nutr. 1995, 125:757S-770S.
12. Chiesa G., Rigamonti E., Lovati M.R., Disconzi E., Soldati S., Sacco M.G., Cato E.M., Patton V., Scanziani E., Vezzoni P., Arnoldi A., Locati D., Sirtori C.R. Reduced mammary tumor progression in a transgenic mouse model fed an isoflavone-poor soy protein concentrate. Mol. Nutr. Food Res. 2008, 52:1121-1129.
13. Losso J.N. The biochemical and functional food properties of the Bowman-Birk Inhibitor. Crit. Rev. Food Sci. Nutr. 2008, 48:94-118.
14. Banerjee S., Li Y., Wang Z., Sarkar F.H. Multi-targeted therapy of cancer by genistein. Cancer Lett. 2008, 269:226-242.
15. Galvez A.F., de Lumen B.O. A soybean cDNA encoding a chromatin-binding peptide inhibits mitosis of mammalian cells. Nat. Biotechnol. 1999, 17:495-500.
16. Hernández-Ledesma B., Hsieh C.C., de Lumen B.O. Lunasin, a novel peptide for cancer prevention. Peptides 2009, 30:426-430.
17. Galvez A.F., Chen N., Macasieb J., de Lumen B.O. Chemopreventive property of a soybean peptide (Lunasin) that binds to deacetylated histones and inhibits acetylation. Cancer Res. 2001, 61:7473-7478.
18. Lam Y., Galvez A., de Lumen B.O. Lunasin suppresses E1A-mediated transformation of mammalian cells but does not inhibit growth of immortalized and established cancer cell lines. Nutr. Cancer 2003, 47:88-94.
19. Jeong J.B., Jeong H.J., Park J.H., Lee S.H., Lee J.R., Lee H.K., Chung G.Y., Choi J.D., de Lumen B.O. Cancer-preventive peptide lunasin from Solanum nigrum L. inhibits acetylation of core histones H3 and H4 and phosphorylation of retinoblastoma protein (Rb). J. Agric. Food Chem. 2007, 55:10707-10713.
20. de Lumen B.O. Lunasin: a cancer-preventive soy peptide. Nutr. Rev. 2005, 63:16-21.
21. Hsieh C.C., Hernández-Ledesma B., Jeong H.J., Park J.H., de Lumen B.O. Complementary roles in cancer prevention: protease inhibitor makes the cancer preventive peptide lunasin bioavailable. PLoS ONE 2010, 5:e8890.
22. Wolf M.M., Lichtenstein D.R., Singh G. Gastrointestinal toxicity of non-steroidal anti-inflammatory drugs. N. Eng. J. Med. 1999, 340:1888-1899.
23. Elder D.J.E., Hague A., Hicks D.J., Paraskeva C. Differential growth inhibition by the aspirin metabolite salicylate in human colorectal tumor cell lines: enhanced apoptosis in carcinoma and in vitro-transformed adenoma relative to adenoma cell lines. Cancer Res. 1996, 56:2273-2276.
24. Sutherland R.L., Musgrove E.A. Cyclins and breast cancer. J. Mammary Gland Biol. Neoplasia 2004, 9:95-104.
25. Moroy T., Geisen C., Cyclin E. Int. J. Biochem. Cell Biol. 2004, 36:1424-1439.
26. Donzelli M., Draetta G.F. Regulating mammalian checkpoints through Cdc25 inactivation. EMBO Rep. 2003, 4:671-677.
27. 2 checkpoints. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:14795-14800.
28. Mundle S.D., Saberwal G. Evolving intricacies and implications of E2F1 regulation. FASEB J. 2003, 17:569-609.
29. Weinberg R.A. The retinoblastoma protein and cell cycle control. Cell 1995, 81:323-330.
30. Reed J.C. Apoptosis-targeted therapies for cancer. Cancer Cell 2003, 3:17-22.
31. Simstein R., Burow M., Parker A., Weldon C., Beckman B. Apoptosis, hemoresistance, and breast cancer: insights from the MCF-7 cell model system. Exp. Biol. Med. 2003, 228:995-1003.
32. Liu J.P. Studies of the molecular mechanisms in the regulation of telomerase activity. FASEB J. 1999, 13:2091-2104.
33. Dwyer J., Li H., Xu D., Liu J.P. Transcriptional regulation of telomerase activity: roles of the Ets transcription factor family. Ann. N. Y. Acad. Sci. 2007, 1114:36-47.
34. Xu D., Dwyer J., Liu H., Duan W., Liu J.P. Ets2 maintains hTERT gene expression and breast cancer cell proliferation by interacting with c-Myc. J. Biol. Chem. 2008, 283:23567-23580.
35. Jamerson M.H., Johnson M.D., Dickson R.B. Of mice and Myc: c-Myc and mammary tumorigenesis. J. Mammary Gland Biol. Neoplasia 2004, 9:27-37.
36. Berger M.S., Locher G.W., Saurer S., Gullick W.J., Waterfield M.D., Groner B., Hynes N.E. Correlation of c-ERBB-2-gene amplification and protein expression in human-breast carcinoma with nodal status and nuclear grading. Cancer Res. 1988, 48:1238-1243.
37. Bellacosa A., Testa J.R., Moore R., Laure L. A portrait of AKT kinases. Cancer Biol. Ther. 2004, 3:268-275.